Cobra Biologics wins ‘CMO Leadership Award’ in five categories
More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.
Cobra Biologics has been recognised with a CMO Leadership Award 2017 in the five categories Quality, Reliability, Capabilities, Expertise and Compatibility. Presented last night at a reception dinner at The W Hotel in New York City, the awards are organised by Life Science Leader magazine and recipients determined through customer feedback collected by Industry Standard Research (ISR). This year’s research included survey responses from over 339 biopharma and pharma professionals who utilise contract development and manufacturing services.
In their 6th year, the CMO Leadership Awards provide Life Science Leader magazine’s readers with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.
For the 2017 awards, Life Science Leader teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Survey participants were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months ensuring that survey responses are based on actual involvement with contract manufacturers and clear experiential data.
Peter Coleman, CEO Cobra Biologics commented: “I am delighted that Cobra has been selected for a CMO Leadership Award. I believe our reputation in the market for GMP manufacturing services combined with excellent science, and a close rapport with our customers, are the key reasons for our rapid growth over the last 5 years as we strive to become a global leader in biologics contract manufacturing.”
Louis Garguilo, Executive Editor, Life Science Leader
and OutsourcedPharma.com said: “Each year, the CMO Leadership Awards recognise the success that individual drug development and manufacturing organisations have in serving the needs of their biotechnology and pharmaceutical customers and partners. Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the six critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”Andrew Schafer, President of Industry Standard Research said: “Industry Standard Research is honoured to conduct the research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high calibre of qualification required to participate in our contract manufacturing benchmarking research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s research to make confident business decisions based on the experiences of their industry peers.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance